Patented design for all pen injector applications
Engineered to reduce the pain of regular injections for diabetes and other chronic conditions, Nanopass™ 34G Needle for Pen Injectors feature a 22% thinner double-tapered needle and better flow3 than comparable 32G designs. Configured to fit most common pen injectors, Terumos’ asymmetric bevel aims to limit pain by significantly reducing penetration resistance4.
Designed for the subcutaneous injection of therapeutics including insulin and human growth hormones, Nanopass™ 34G Needle for Pen Injectors offer the quality and supply reliability needed to meet drug developers’ toughest parenteral delivery challenges and product commercialization goals.
Patient's comfort in mind5
- The asymmetric needle tip aims to reduce pain dring the insertion as the special shape is expected to cut the skin rather than piercing it. A related observation is displayed in the literature5.
- 34G needle 22% thinner than 32G, decreasing probability of touching pain receptors in the skin
- Optimized flow, less injection force than 32G needles (insulin)3
Engineered for automated environments
- Individually packed and sealed in an ergonomic plastic case for automated assembly and easier patient handling
Regulatory and Quality Aspects
References
1 Based on research by Terumo Corporation in November 2020
2 Based on research by Terumo Corporation in May 2017
3 Study NP34_basic technical comparison Asakura T., 2013, Jpn J Med Pharm Sci 69(1) 147-155
4 Patented Technology
5 Pen needle design influences ease of insertion, pain and skin trauma in subjects with type 2 diabetes Kezia A Praestmark, 1, E, Morten L Jenzen, 3 Nils B Madsen, 2 JOnas Kildegaard, 4 Bente M Stallknecht 1
